Endonovo Therapeutics, Inc. (ENDV)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Jul 29, 2026, 4:00 PM EST
Endonovo Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
Period Ending | Sep '23 Sep 30, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 |
Cash & Equivalents | - | 0 | 0.09 | 0.01 | 0.02 | 0.38 |
Cash & Short-Term Investments | - | 0 | 0.09 | 0.01 | 0.02 | 0.38 |
Cash Growth | - | -99.89% | 540.36% | -28.97% | -95.02% | 320.47% |
Receivables | - | - | 0 | 0 | 0.02 | 0 |
Prepaid Expenses | 0.04 | 0.02 | 0.01 | 0.03 | 0.02 | - |
Total Current Assets | 0.04 | 0.02 | 0.09 | 0.05 | 0.06 | 0.38 |
Property, Plant & Equipment | - | - | - | 0 | 0.01 | 0.01 |
Other Intangible Assets | 0.78 | 1.27 | 1.91 | 2.56 | 3.21 | 3.85 |
Total Assets | 0.82 | 1.28 | 2.01 | 2.61 | 3.27 | 4.24 |
Liabilities
Fiscal Year | TTM | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
Period Ending | Sep '23 Sep 30, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 |
Accounts Payable | 0.93 | 0.88 | 0.66 | 0.7 | 0.6 | 0.16 |
Accrued Expenses | 9.28 | 7.99 | 6.42 | 5.29 | 3.75 | 3.03 |
Short-Term Debt | 0.1 | 0.11 | 0.13 | 0.14 | 0.17 | 0.27 |
Current Portion of Long-Term Debt | 6.95 | 7.04 | 7.06 | 6.49 | 8.51 | 7.59 |
Other Current Liabilities | 6.44 | 17.36 | 3.44 | 4.2 | 10.6 | 4.43 |
Total Current Liabilities | 23.7 | 33.38 | 17.7 | 16.83 | 23.62 | 15.48 |
Other Long-Term Liabilities | 0.08 | 0.08 | 0.08 | 0.16 | 0.16 | 0.16 |
Total Liabilities | 23.78 | 33.46 | 17.78 | 16.98 | 23.78 | 15.63 |
Shareholders' Equity
Fiscal Year | TTM | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
Period Ending | Sep '23 Sep 30, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 |
Common Stock | 0.03 | 0.02 | 0.01 | 0 | 0 | 0 |
Additional Paid-In Capital | 43.64 | 42.92 | 40.66 | 38.96 | 32.43 | 24.23 |
Retained Earnings | -66.63 | -75.12 | -56.44 | -53.34 | -52.93 | -35.62 |
Comprehensive Income & Other | -0 | -0 | -0 | -0 | -0 | -0 |
Total Common Equity | -22.96 | -32.18 | -15.77 | -14.37 | -20.5 | -11.39 |
Shareholders' Equity | -22.96 | -32.18 | -15.77 | -14.37 | -20.5 | -11.39 |
Total Liabilities & Equity | 0.82 | 1.28 | 2.01 | 2.61 | 3.27 | 4.24 |
Additional Metrics
Fiscal Year | TTM | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
Period Ending | Sep '23 Sep 30, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 |
Total Debt | 7.06 | 7.15 | 7.18 | 6.63 | 8.68 | 7.86 |
Net Cash (Debt) | -7.06 | -7.15 | -7.1 | -6.62 | -8.66 | -7.48 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -0.03 | -0.05 | -0.12 | -0.54 | -12.41 | -20.65 |
Filing Date Shares Outstanding | 318.75 | 270.29 | 149.53 | 53.58 | 8.81 | 0.53 |
Total Common Shares Outstanding | 318.75 | 213.23 | 74.5 | 24.54 | 1.19 | 0.43 |
Working Capital | -23.66 | -33.37 | -17.61 | -16.78 | -23.56 | -15.1 |
Book Value Per Share | -0.07 | -0.15 | -0.21 | -0.59 | -17.24 | -26.43 |
Tangible Book Value | -23.74 | -33.45 | -17.69 | -16.93 | -23.71 | -15.24 |
Tangible Book Value Per Share | -0.07 | -0.16 | -0.24 | -0.69 | -19.94 | -35.37 |
Machinery | - | - | - | 0.09 | 0.09 | 0.09 |